/PRNewswire/ The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David s Medical Center participated in a clinical study to evaluate the.
Share:
Arrhythmia, a condition that causes the heart to beat with an irregular or abnormal rhythm, is the fourth leading disease in the United States. Untreated or undiagnosed, arrhythmias can increase the risk of severe health complications including stroke or even death.
Medtech company BioSig Technologies (NASDAQ: BSGM) has developed the PURE EP System, a technology that aims to improve the visuals of cardiac signals for surgeons that treat irregular heartbeats. The company hopes this will encourage more arrhythmia patients to elect for surgical treatment a therapy option that is increasingly proving more effective than pharmaceutical alternatives.
With major players in the space like Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT) and Abbott (NYSE: ABT) grabbing the attention of investors, let’s look at why and how BioSig is claiming a name for itself in the industry.
Andrea Natale, M.D. Joins Ensite Vascular’s Medical Advisory Board
Share Article OLATHE, Kan. (PRWEB) May 13, 2021 Ensite Vascular announces that Andrea Natale, M.D., F.A.C.C, F.H.R.S., F.E.S.C., Executive Medical Director of Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, has accepted an appointment to the company’s Medical Advisory Board (MAB).
Dr. Natale is a world-recognized leader in the field of electrophysiology and known as a dedicated clinician, academician and researcher. He has authored more than 600 publications related to the treatment of arrhythmia. Dr. Natale has been an invited speaker at hundreds of symposia and conferences around the world and has served on multiple editorial boards. He is editor-in-chief of the Journal of Interventional Cardiac Electrophysiology and the first editor-in-chief of the Journal of Atrial Fibrillation, which he founded. In add
BioSig Technologies increases patient case goal to 1,500 procedures by end of 2021
The company previously announced its target to complete 1,000 patient cases in 2021, having delivered 425 procedures by the end of 2020 BioSig’s non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology
BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has increased its patient case goal to at least 1,500 procedures by the end of 2021.
BioSig’s non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology. The system provides essential diagnostic signals with high clinical value in all cardiac ablations that treat irregular heartbeats or arrhythmias.
BioSig says physicians at Mayo Clinic’s campus in Phoenix, Arizona have started using its PURE EP System in patient cases treating cardiac arrhythmias
The 30-day clinical evaluation of the PURE EP System is being conducted by the cardiac electrophysiologists Win-Kuang Shen, Hichan El Masry, Arturo Valverde, and Luis Scott Mayo Clinic cares for more than one million people a year, from all 50 states and nearly 140 countries and the institution has consistently ranked at or near the top of the ‘Best Hospitals Honor Roll’
BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that physicians at Mayo Clinic’s campus in Phoenix, Arizona have started using the company’s PURE EP System in patient cases treating cardiac arrhythmias.